News
Biocon Biologics receives marketing authorizations for Vevzuo and Evfraxy biosimilars for bone-related diseases in the UK.
Biocon Biologics Ltd received UK approval for Vevzuo and Evfraxy, biosimilars of Denosumab. Vevzuo is approved for ...
New Delhi: Biocon Ltd on Monday said its arm Biocon Biologics Ltd has received marketing authorisations from the Medicines ...
3h
Capital Market on MSNBiocon gets MHRA UK approval for marketing Denosumab biosimilars 'Vevzuo' & 'Evfraxy'Vevzuo is authorized for the prevention of skeletal related events (pathological fracture, radiation to bone, spinal cord ...
Biocon Biologics announced that the Medicines and Healthcare products Regulatory Agency (MHRA) granted marketing authorisations in the United Kingdom (UK) for Vevzuo and Evfraxy, biosimilars of ...
Biocon Ltd. plans to file for regulatory approvals of generic versions of Novo Nordisk A/S’s Ozempic and Wegovy in key ...
Biocon share price gained 2.5 per cent after reports suggested that the company is planning to file for generic versions of ...
Bengaluru: A war of words has erupted between Biocon founder Kiran Mazumdar-Shaw and Karnataka Chief Minister Siddaramaiah on ...
Biocon Biologics receives UK MHRA approval for Vevzuo & Evfraxy, biosimilars of Denosumab, to treat bone diseases in adults & ...
Clinical studies have demonstrated that both biosimilars are comparable in safety and efficacy to the reference product, the ...
Bengaluru: Biocon Biologics Ltd, a fully integrated global biosimilars company and subsidiary of Biocon Ltd., has received ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results